RMD ResMed Inc.

Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution

Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution

Brand Evolution Unites Brands Under One Resmed Identity to Make Better Sleep and Breathing Health More Accessible to Everyone

SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a comprehensive brand evolution designed to unify its brand portfolio to serve more people and healthcare providers worldwide and reflect growing direct to consumer engagement.

For 35 years, Resmed has pioneered innovations in respiratory therapy, including CPAP therapy and digital health solutions. The company’s last major brand update in 2014 marked its shift to connectivity, introducing cloud-connected medical devices that revolutionized sleep apnea therapy. Today, Resmed is taking the next step – transforming into a fully unified health technology brand that serves millions of consumers, healthcare professionals, and software users worldwide.

An estimated 2.3+ billion people worldwide suffer from sleep apnea, insomnia, COPD, or other respiratory insufficiency. 1 2 3 Additionally, highlights the widespread impact of poor sleep, with one-third of respondents reporting sleep difficulties, including trouble falling asleep (34%) and staying asleep (29%).4 Through its brand evolution, Resmed accelerates its ability to reach people where they are – and help them sleep better, breathe better, and improve their overall health and well-being.

“We are at a pivotal moment in health – sleep and breathing health are gaining the attention once reserved for diet and exercise, with consumers taking a more proactive role in their care,” said Katrin Pucknat, Resmed’s Chief Marketing Officer. “Our brand evolution is more than a new look – it’s a bold step forward in our strategy to make sleep and breathing health a mainstream priority in global healthcare.”

As part of the brand evolution, Resmed plans to consolidate its brands, products, and services under a single Resmed brand over the next couple of years, creating a more streamlined view for both consumers and healthcare providers. This transformation is accompanied by a new visual identity, redesigned logo, and refreshed brand voice, reinforcing Resmed’s position as an approachable, people-centered, and forward-thinking health technology company.

The brand evolution aligns with Resmed’s mission to create life-changing health technologies that people love and coincides with three major market-facing initiatives aimed at reshaping perceptions of sleep therapy and expanding awareness of sleep apnea treatment:

  • The company’s first U.S. consumer campaign aimed at destigmatizing CPAP therapy and positioning sleep health as more approachable
  • A targeted primary care physician (PCP) education campaign starting in the U.S. to help drive earlier diagnosis and intervention for sleep apnea
  • A sleep health awareness campaign in key markets in Asia Pacific and Europe focused on helping to overcome the barriers to seeking treatment for sleep apnea

“Resmed has evolved beyond its origins as a CPAP device and mask manufacturer. Our new brand reflects who we are today – a global leader in health technology, delivering solutions that help people rise to their full potential through better sleep and breathing, with care delivered in the home,” said Mick Farrell, Resmed’s Chairman & CEO. “With this evolution, we are reaffirming our commitment to empowering 500 million people worldwide to achieve their full health potential by 2030 and changing the delivery of healthcare.”

To learn more about Resmed’s brand evolution, visit .

About Resmed

Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at and follow @Resmed.

  
For Media For Investors
  
Julia MoserMike Ott or Wendy Wilson
 

_________________________________

1 Benjafield et al Lancet Respir Med 2019

2 Benjafield et al Sleep Med (suppl) 2024

3 Boers et al JAMA Network Open 2023

4 Based on over 30,000 respondents across 13 markets surveyed as part of the ResMed 2025 Global Sleep Survey between December 12-28, 2024)



EN
11/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ResMed Inc.

 PRESS RELEASE

Resmed Inc. Announces Results for the First Quarter of Fiscal Year 202...

Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026 Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis Gross margin up 290 bps to 61.5%; non-GAAP gross margin up 280 bps to 62.0%Income from operations increased 15%; non-GAAP income from operations up 19%Diluted earnings per share of $2.37; non-GAAP diluted earnings per share of $2.55Operating cash flow of $457 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at  SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) to...

 PRESS RELEASE

Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 202...

Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025 SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2026 on Thursday, October 30, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:  •Location: •Date:Thursday, October 30, 2025 •Time:1:30 p.m. PD...

 PRESS RELEASE

Resmed Announces Participation in the Bank of America Global Healthcar...

Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025 SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the Bank of America Global Healthcare Conference 2025 on Tuesday, September 23, 2025, beginning at approximately 1:20 p.m. (British Summer Time) in London. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting . The audio-only webcast replay w...

 PRESS RELEASE

Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Pr...

Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority New global clinical insights initiative debuts at World Sleep Congress 2025 to help drive innovation in sleep health care SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the launch of , a global clinical insights initiative dedicated to advancing the science and understanding of sleep health. Sleep Institute partners with clinicians, researchers, policymakers, and healt...

 PRESS RELEASE

Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adul...

Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds Published in The Lancet Respiratory Medicine, research reveals sharp rise in OSA, especially among women, highlighting the need for earlier diagnosis, preventative strategies, and personalized care SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark study in projecting a significant rise in obstructive sleep apnea (OS...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch